Tobemstomig

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Non-Small Cell Lung CancerHepatocellular CarcinomaRenal Cell CarcinomaSquamous Cell CarcinomaLiver CancerTriple-Negative Breast CancerAdvanced Liver Cancers

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

1

Yervoy

Bristol-Myers Squibb

Preclinical

312

Tobemstomig

Roche

Phase 2

13

Gemzar

GGynecologic Oncology Group

Preclinical

724

PORTRAZZA

Eli Lilly

Preclinical

85

Imjudo

AstraZeneca

Preclinical

56

Vizimpro

Pfizer

Preclinical

47

Immunotherapy

Bristol-Myers Squibb

Preclinical

128

Remeron

OOrganon and Co

Preclinical

19

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

210

Treatment

GSK

Preclinical

1Show 19 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Squamous Cell Carcinoma1 trial

A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

Completed·Roche·Phase 2·NCT04785820·206 enrolled

Non-Small Cell Lung Cancer1 trial

A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer

Active, not recruiting·Roche·Phase 2·NCT05775289·182 enrolled

Hepatocellular Carcinoma1 trial

A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma

Completed·Roche·Phase 1/2·NCT05908786·62 enrolled

Triple-Negative Breast Cancer1 trial

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Active, not recruiting·Roche·Phase 2·NCT05852691·83 enrolled

Metastatic Urothelial Cancer1 trial

A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

Active, not recruiting·Roche·Phase 2·NCT05645692·204 enrolled

2 more indications

Renal Cell Carcinoma1 trial

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Active, not recruiting·Roche·Phase 2·NCT05805501·199 enrolled

Advanced Liver Cancers1 trial

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

Recruiting·Roche·Preclinical·NCT04524871·518 enrolled

Details

Drug Info

Related News